ValiSeek Limited was formed as a Joint Venture single asset company in 2014 to progress cancer program VAL401 through early stage clinical trials to a stage attractive for out-licensing.
ValiSeek is looking to initiate detailed licensing discussions prior to completion for co-development or out-licensing on a regional, global or disease specific basis to ensure a smooth continuation of their project VAL401.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature